This site is intended for health professionals only
Sunday 21 April 2019
Share |

Topic: Diabetes

November 9, 2018
Diabetes prescriptions cost NHS over £1bn a year, data reveals

NHS England spends over £1bn per year on diabetes prescriptions, data has revealed.
 
A report published yesterday (8 November) by NHS Digital showed that the cost of prescriptions for diabetes has grown by £422m in a decade, reaching more than £1bn in 2017/18.
 

September 28, 2018
Hannah Beba is a senior pharmacist practising in the diabetes and endocrinology fields at the County Durham and Darlington NHS Foundation Trust. She is also one of the charity Diabetes UK clinical champions and an independent prescriber. She talks to Léa Legraien about her successes, challenges and love for the profession.

Hannah Beba is a senior pharmacist practising in the diabetes and endocrinology fields at the County Durham and Darlington NHS Foundation Trust. She is also one of the charity Diabetes UK clinical champions and an independent prescriber.
 
She talks to Léa Legraien about her successes, challenges and love for the profession.
 
 
Q Why did you become a pharmacist?
 
 

September 28, 2018
Hannah Beba is a senior pharmacist practising in the diabetes and endocrinology fields at the County Durham and Darlington NHS Foundation Trust. She is also one of the charity Diabetes UK clinical champions and an independent prescriber. She talks to Léa Legraien about her successes, challenges and love for the profession.

Hannah Beba is a senior pharmacist practising in the diabetes and endocrinology fields at the County Durham and Darlington NHS Foundation Trust. She is also one of the charity Diabetes UK clinical champions and an independent prescriber.
 
She talks to Léa Legraien about her successes, challenges and love for the profession.
 
 
Q Why did you become a pharmacist?
 
 

March 7, 2018
Danish pharmaceutical company Novo Nordisk’s diabetes drug, semaglutide, which could also be used to treat obesity, has passed its first Phase III clinical trial. Semaglutide is taken once daily as a tablet and works by increasing insulin production

As rates of diabetes continue to rise, the hunt for new drugs to tackle the metabolic disease is imperative. In 2014 there were an estimated 422 million people with diabetes, compared to just 108 million in 1980.

 

Although there are a range of treatment options available for type 2 diabetes, many target the symptoms rather than the root cause and may have adverse side effects. A further difficulty is the close connection between diabetes and obesity, which is causing cases to increase.

 

March 7, 2018
Danish pharmaceutical company Novo Nordisk’s diabetes drug, semaglutide, which could also be used to treat obesity, has passed its first Phase III clinical trial. Semaglutide is taken once daily as a tablet and works by increasing insulin production

As rates of diabetes continue to rise, the hunt for new drugs to tackle the metabolic disease is imperative. In 2014 there were an estimated 422 million people with diabetes, compared to just 108 million in 1980.

 

Although there are a range of treatment options available for type 2 diabetes, many target the symptoms rather than the root cause and may have adverse side effects. A further difficulty is the close connection between diabetes and obesity, which is causing cases to increase.

 

September 14, 2017
In people with type 2 diabetes, Xultophy® (insulin degludec/liraglutide) significantly reduced a number of risk factors associated with an increased risk of cardiovascular disease, compared to basal insulin

According to a new post-hoc analysis presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD 2017), people treated with Xultophy® had significantly lower systolic blood pressure, lower total cholesterol as well as lower low-density lipoprotein cholesterol (so-called 'bad cholesterol'), and significant weight changes in favour of Xultophy® compared to people treated with basal insulin (insulin glargine U100 or insulin degludec).

May 19, 2017
The Forum for Injection Technique (FIT) UK has published the latest edition of its UK Injection and Infusion Technique Recommendations

The Forum for Injection Technique (FIT) UK, which provides evidence-based best practice recommendations on diabetes injection technique, has published the latest edition of its UK Injection and Infusion Technique Recommendations, including for the first time a new set of six ‘Golden Rules’.

 

May 19, 2017
The Forum for Injection Technique (FIT) UK has published the latest edition of its UK Injection and Infusion Technique Recommendations

The Forum for Injection Technique (FIT) UK, which provides evidence-based best practice recommendations on diabetes injection technique, has published the latest edition of its UK Injection and Infusion Technique Recommendations, including for the first time a new set of six ‘Golden Rules’.

 

September 16, 2016
Novo Nordisk today announced that the CHMP has adopted a positive opinion to extend the use of NovoRapid® (insulin aspart) in the EU for children with diabetes from as young as one year old

September 16, 2016
Novo Nordisk today announced that the CHMP has adopted a positive opinion to extend the use of NovoRapid® (insulin aspart) in the EU for children with diabetes from as young as one year old

September 16, 2016
Results were presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes 2016

Novo Nordisk has announced that the progression of kidney damage was significantly lower with Victoza® treatment vs placebo, as measured by urinary albumin creatinine ratio, both added to standard of care in 9340 adults with type 2 diabetes at high cardiovascular (CV) risk.

 

Similar significant results were observed between Victoza® and placebo across subgroups (with no, mild or moderate renal impairment).

 

September 16, 2015
Findings from a head-to-head trial have demonstrated a significantly greater reduction in blood sugar for liraglutide compared to lixisenatide in adults with type 2 diabetes

Findings from a head-to-head trial comparing Victoza® (liraglutide) and lixisenatide, both in combination with metformin, have demonstrated a significantly greater reduction in blood sugar (measured by HbA1c) for liraglutide compared to lixisenatide in adults with type 2 diabetes. (1) The results from the LIRA-LIXI trial were announced at the 51st Annual Meeting of the European Association for the Study of Diabetes (EASD) in Stockholm, Sweden.

 

September 16, 2015
Findings from a head-to-head trial have demonstrated a significantly greater reduction in blood sugar for liraglutide compared to lixisenatide in adults with type 2 diabetes

Findings from a head-to-head trial comparing Victoza® (liraglutide) and lixisenatide, both in combination with metformin, have demonstrated a significantly greater reduction in blood sugar (measured by HbA1c) for liraglutide compared to lixisenatide in adults with type 2 diabetes. (1) The results from the LIRA-LIXI trial were announced at the 51st Annual Meeting of the European Association for the Study of Diabetes (EASD) in Stockholm, Sweden.

 

September 15, 2015
Patients with type 2 diabetes also reported higher satisfaction with Tresiba® U200 highlighting an overall preference versus insulin glargine U100

New data presented today at the 51st annual meeting of the European Association for the Study of Diabetes (EASD) show that patients with type 2 diabetes receiving the U200 formulation of Tresiba® (insulin degludec) experienced significantly lower rates of confirmed hypoglycaemia and significantly reduced mean fasting blood glucose compared to those receiving insulin glargine U100. (1) Tresiba® U200 is twice as concentrated as U100, allowing patients to inject up to 160 units in a single injection, rather than in two separate injections.

 

September 15, 2015
Patients treated with Xultophy® achieved significant improvements in treatment related impact measurements compared to intensifying insulin glargine

Data from the DUAL™ V trial investigating the efficacy and safety of Xultophy® (insulin degludec/liraglutide; IDegLira), in type 2 diabetes patients (T2D) uncontrolled on insulin glargine, were presented at the 51st European Association for the Study of Diabetes (EASD) Annual Meeting. (1)

 

September 15, 2015
Patients treated with Xultophy® achieved significant improvements in treatment related impact measurements compared to intensifying insulin glargine

Data from the DUAL™ V trial investigating the efficacy and safety of Xultophy® (insulin degludec/liraglutide; IDegLira), in type 2 diabetes patients (T2D) uncontrolled on insulin glargine, were presented at the 51st European Association for the Study of Diabetes (EASD) Annual Meeting. (1)

 

September 15, 2015
Advice from Philip Newland-Jones, the Royal Pharmaceutical Society's Leadership Award winner

With the dramatic rise in the number of people living with type 2 diabetes there is an urgent need for more pharmacists who specialise in diabetes, the Royal Pharmaceutical Society's Leadership Award winner has advised.

 

Philip Newland-Jones, an Advanced Specialist Pharmacist Practitioner at University Hospital Southampton NHS Foundation Trust, won the award on Sunday 13 September for his outstanding leadership across several clinical, education and research fields within the area of diabetes, both locally and nationally.

June 26, 2015
Novo Nordisk announced that the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the expanded use of Levemir® (insulin detemir) in children with diabetes as young as one year old

There are an estimated 497,100 children living with type I diabetes globally and incidence is increasing in many countries. (1) Young children with type I diabetes can be difficult to treat as their needs are in constant flux during growth and development, (2) with children aged six and under at greatest risk of severe hypoglycaemia and acute diabetes complications. (3)
 

 

June 11, 2015
New data published from the University of Barcelona shows OZURDEX® (dexamethasone 0.7mg intravitreal implant) provides significant improvements in visual acuity, compared to baseline, in patients affected by diabetic macular oedema (DMO). This was observed in patients that had not responded to two or more DMO treatments (refractory, n=40), as well as in those that had not previously received DMO therapy (treatment-naïve, n=36). (1)

New data published from the University of Barcelona shows OZURDEX® (dexamethasone 0.7mg intravitreal implant) provides significant improvements in visual acuity, compared to baseline, in patients affected by diabetic macular oedema (DMO). This was observed in patients that had not responded to two or more DMO treatments (refractory, n=40), as well as in those that had not previously received DMO therapy (treatment-naïve, n=36). (1)

June 9, 2015
Novo Nordisk announced that Xultophy® (insulin degludec/liraglutide; IDegLira), the first ever treatment combining two existing treatments, long acting (basal) insulin (insulin degludec, Tresiba®) (1) and GLP-1 receptor agonist (liraglutide, Victoza®) (2) in one pen, has been launched in the United Kingdom

Novo Nordisk announced that Xultophy® (insulin degludec/liraglutide; IDegLira), the first ever treatment combining two existing treatments, long acting (basal) insulin (insulin degludec, Tresiba®) (1) and GLP-1 receptor agonist (liraglutide, Victoza®) (2) in one pen, has been launched in the United Kingdom.

 

June 8, 2015
New IntroDia™ Survey patient data was presented at American Diabetes Association’s® (ADA) 75th Scientific Sessions. IntroDia™ is an initiative of Boehringer Ingelheim and Lilly in partnership with the International Diabetes Federation.

New IntroDia™ Survey patient data was presented at American Diabetes Association’s®  (ADA) 75th Scientific Sessions. IntroDia™ is an initiative of Boehringer Ingelheim and Lilly in partnership with the International Diabetes Federation.

May 29, 2015
Synjardy® has been granted marketing authorisation by the European Commission for the treatment of adults with type II diabetes (T2D) in the European Union (EU). Synjardy® is a new single-pill combination therapy from the Boehringer Ingelheim and Eli Lilly and Company diabetes alliance.

Synjardy® has been granted marketing authorisation by the European Commission for the treatment of adults with type II diabetes (T2D) in the European Union (EU). Synjardy® is a new single-pill combination therapy from the Boehringer Ingelheim and Eli Lilly and Company diabetes alliance.

Synjardy® combines two products with different mechanisms of action to improve glycaemic control in patients with T2D. Side effects identified with Synjardy® are consistent with known safety profiles of the individual compounds.
 

May 28, 2015
This article briefly reviews the strategies used to effectively treat type 2 diabetes patients that are unable to tolerate metformin

 

March 30, 2015
Empagliflozin when added to metformin HCl lowers blood glucose, body weight and blood pressure. Side effects identified with empagliflozin plus metformin HCl were in line with the known safety profile of the individual compounds empagliflozin and metformin.

Empagliflozin when added to metformin HCl lowers blood glucose, body weight and blood pressure. Side effects identified with empagliflozin plus metformin HCl were in line with the known safety profile of the individual compounds empagliflozin and metformin.

You are leaving www.nursinginpractice.com

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?

Close

Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.


GET INVOLVED: SIGN OUR E-PETITION

Close

Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher




http://www.facebook.com/NursinginPracticeMagazine